Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities. Etoricoxib is a potent, orally active & highly selective cyclooxygenase-2 (COX-2) inhibitor. COX-2 is primarily responsible for the synthesis of prostanoid mediators of pain, inflammation and fever. Etoricoxib decreases these clinical signs and symptoms effectively with decreased GI toxicity. Moreover it has no effect on platelet function.
(in Tablet form)
The recommended dose for adult and patient over 16 years:
Acute pain: 120 mg once daily. Etoricoxib 120 mg should be used only for acute symptomatic period, limited to a maximum of 8 days treatment.
Chronic musculoskeletal pain: 60 mg once daily.
Osteoarthritis: 30 mg once daily, increased if necessary to 60 mg once daily.
Rheumatoid arthritis and ankylosing spondylitis: 90 mg once daily.
Acute gout: 120 mg once daily for max. 8 days. Max. 60 mg daily in mild hepatic impairment; max. 60 mg on alternate days or 30 mg once daily in moderate hepatic impairment.
Manufacturer: Square Pharmaceutical Ltd.